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The authors advised that they have introduced errors while preparing this article which were oversighted by all authors.

On page 1541, in Results section, Risk of moderate or severe COPD exacerbation; (rate ratio, 0.81; 95% CI, 0.73 to 0.89, *I*^2^=29%; Figure 1) should be (rate ratio, 0.80; 95% CI, 0.71 to 0.90, *I*^2^=37%; Figure 1); and in Secondary outcomes, (MD, −153; 95% CI, −2.23 to −0.84, *I*^2^=21%; Figure 3) should be (MD, −1.53; 95% CI, −2.23 to −0.84, *I*^2^=21%; Figure 3).

On page 1543, Figure 2 should be presented as below.

On Page 1544, Discussion section, (vs LABA/LAMA, risk ratio, 0.99; 95% CI, 0.44 to 2.27, *I*^2^=31%; vs ICS/LABA, risk ratio, 1.00; 95% CI, 0.53 to 1.89, *I*^2^=0%; vs separate triple therapy, risk ratio, 0.48; 95% CI, 0.18 to 1.28, *I*^2^=49%; [[Figure S6](https://reurl.cc/5NZY6)]{.ul}) should be: (vs LABA/LAMA, risk ratio, 0.74; 95% CI, 0.50 to 1.10, *I*^2^=31%; vs ICS/LABA, risk ratio, 1.00; 95% CI, 0.53 to 1.89, *I*^2^=0%; vs separate triple therapy, risk ratio, 0.48; 95% CI, 0.18 to 1.28, *I*^2^=49%; [[Figure S6](https://reurl.cc/5NZY6)]{.ul}).

On page 1544, Adverse events section should be as the following:

Single inhaler triple therapy was associated with a significantly higher risk of pneumonia compared with LABA/LAMA dual therapy (risk ratio, 1.38, 95% CI, 1.14 to 1.67, *I*^2^=0%), but no significant differences were found when it was compared with ICS/LABA dual therapy (risk ratio, 1.24, 95% CI, 0.83 to 1.85, *I*^2^=48%) or separate triple therapy (risk ratio, 0.88, 95% CI, 0.51 to 1.52, *I*^2^=25%; Figure 4). The risk of lower respiratory tract infection (LRTI) was investigated however, no significant differences were found between single inhaler triple therapy and the three alternative treatments (vs LABA/LAMA, risk ratio, 0.90; 95% CI, 0.73 to 1.11, *I*^2^=0%; vs ICS/LABA, risk ratio, 1.02; 95% CI, 0.85 to 1.23, *I*^2^=0%; vs separate triple therapy, risk ratio, 0.91; 95% CI, 0.37 to 2.26, *I*^2^=84%; [[Figure S9](https://reurl.cc/5NZY6)]{.ul}). In addition, there were no significant differences observed between single inhaler triple therapy and the comparative treatments in regard to the risk of treatment emergent adverse events, serious adverse events, and cardiovascular events ([[Figure S10-- S12](https://reurl.cc/5NZY6)]{.ul} ).
